Mentions
Extended reach
Total likes
Video views
AI synopsis
The evaluations reflect a strong consensus on the therapeutic promise of GLP-1, with posts using technical language like 'receptor agonists,' 'clinical data,' and 'market growth,' all implying a high level of interest. Simultaneously, mentions of side effects, regulatory evaluations, and market influence reveal deep engagement and moderate potential for changing medical practice, which justifies the overall scores.
Most discussions recognize GLP-1's crucial role in weight management and treatment of metabolic disorders, showing general support for its therapeutic potential.
Numerous posts delve into the mechanisms, new drug developments, and societal implications, indicating high curiosity and engagement.
Posts reference specific drugs, clinical trials, potential side effects, and regulatory issues, demonstrating deep involvement and detailed analysis.
The discussions highlight significant advances in treatment options and market growth, suggesting moderate impact on healthcare practices and policy.
@TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to
Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes. Research findings from the ACHIEVE-1 phase 3 trial are summarized in a new Quick Take video. https://t.co/NBFIqmeGy5 https://t.co/O6rXMQMso2
Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descarga: https://t.co/YG5gDNiha3 @mdballesteros @isidoro_cano @diabeteSEEN @fjavesc @DiegoBellido2 @mbotana @sandradurandoc @ObesitySeen @Judithendo https://t.co/CFJEu6Vqcg
active ingredient but can be used to treat different conditions. Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. By reducing body weight,
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss https://t.co/m88yKUpNGy https://t.co/ZcjXD7shEC
How do weight loss drugs like Wegovy work? In the latest edition of #PeriodicGraphics in @cenmag.bsky.social we take a look at the science and history behind these drugs: cen.acs.org/biological-c... #ChemSky
Inulin-type fructans supplementation effectively improves key markers of blood sugar control, such as fasting blood glucose, HbA1c, fasting insulin, and insulin resistance, especially in people with prediabetes and type…
This video explores the mechanisms of GLP-1 Semaglutide (Ozempic), its impact on weight loss, and potential adverse effects. It also covers the hormone's roles in insulin regulation, appetite reduction, and…
This video explores the mechanisms of GLP-1, a hormone involved in insulin secretion, gastric emptying, and appetite regulation. It discusses its role in treating type 2 diabetes and potential use in obesity and…
GLP-1 is a hormone with diverse roles, including stimulating insulin, slowing gastric emptying, reducing food intake, and affecting the heart and brain. Biochemically modified GLP-1 receptor agonists are used to treat…
This video explains how Ozempic (semaglutide) works in weight management, blood sugar control, and obesity treatment, highlighting potential risks of misuse based on recent popularity and scientific research.
This video explains how researchers have discovered a new treatment for diabetes and weight loss using Gila monster saliva, highlighting the importance of the hormone GLP-1 which stimulates insulin and reduces appetite…
Hormone optimization is essential for maintaining a healthy weight. This episode discusses leptin's role in fat regulation and how to naturally optimize hormones for better weight management without harmful drugs.
https://t.co/yGeOoBNlsM
REMINDER - UPDATED TOPIC - Virtual press conference on global health issues, with focus on launch of WHO guideline concerning glucagon-like peptide-1 (GLP-1) therapies and obesity in adults https://t.co/6kmOGdRjEd
REMINDER - UPDATED TOPIC - Virtual press conference on global health issues, with focus on launch of WHO guideline concerning glucagon-like peptide-1 (GLP-1) therapies and obesity in adults https://t.co/ktpo0GNIaG
GLP-1 in a capsule Orforglipron is currently being researched as a once daily oral glucagon like peptide-1 (GLP-1) receptor agonist Unlike injectable GLP-1s Orforglipron is a non-peptide small molecule, making simpler to administer without the need for injections or
RT @JAMAInternalMed: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-st…
RT @JAMAOnc: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed w…
RT @JAMASurgery: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-stream…
RT @JAMASurgery: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-stream…
Headache Centre of the University of Naples gave the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide to 26 adults with obesity and chronic migraine (defined as 15 or more headache days per month). Patients reported an average of 11 fewer headache days per month
RT @JAMA_current: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-strea…
RT @JAMACardio: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streame…
RT @JAMA_current: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-strea…
RT @JAMAOnc: On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed w…
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @who.int guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4p0DXIF
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/DbYbEry7ET https://t.co/0nVbNjlNOb
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/hzUm2K2qmt https://t.co/tWlP57mmWT
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/FYYHlmwWVV https://t.co/TD1sZb0PQP
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/WmfDVBXtXN https://t.co/FblekswAw1
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/mlCXFxmMU4 https://t.co/PYYx0rBeHo
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/QQUnmtekGg https://t.co/z5RUVqshc0
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/4s5Y2Mu74e https://t.co/4EoAnsPBdm
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/3M3eDmX
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/3KlWQH7
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/48lzVnk
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/OSAEx5XNiX https://t.co/mUm7ZpH9mK
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/Xr0KaNxN82 https://t.co/hxkvhzMliU
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/6D2nFaspLO https://t.co/cf0gW06ZjS
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/lZD9F8DAk2 https://t.co/Ran6N3IUXH
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/J0aRm2Xhld https://t.co/NuCUpPdVbS
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: https://t.co/OM2abBixnH https://t.co/WqKunmOJUN
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/48C1B8E
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4p33ssZ
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/3LUxdh8
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4of3Zqx
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4pwD8Y7
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/4adNgAr
On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #GLP-1 therapy and adults with #obesity. Register for the webinar: ja.ma/3XOwS22
UPDATED TOPIC - Virtual press conference on global health issues, with focus on launch of WHO guideline concerning glucagon-like peptide-1 (GLP-1) therapies and obesity in adults https://t.co/s8mIb7Rke7
UPDATED TOPIC - Virtual press conference on global health issues, with focus on launch of WHO guideline concerning glucagon-like peptide-1 (GLP-1) therapies and obesity in adults https://t.co/VFbRSPmJ9I
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
@hormonedietdoc Ozempic is a brand-name prescription medication containing the active ingredient semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is primarily FDA-approved for treating type 2 diabetes in adults, where it helps improve blood sugar control by mimicking the
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
Postpartum Prescription of GLP‑1 Drugs Has Increased Sharply, Study Finds Prescription rates climb to near‑record levels According to a new analysis of nationwide pharmacy data, the use of glucagon‑like peptide‑1 (GLP‑1) agonists among women who have recently given birth has surged drama
RT @DanielJDrucker: New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors,…
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss www.novonordisk.com/content/nnco...
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss https://t.co/m88yKUpNGy https://t.co/ZcjXD7shEC
WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults https://www.newsbeep.com/au/307436/ Obesity affects more than one billion people worldwide and remains a leading cause of chronic disease and…
@growing_daniel True. Semaglutide is a fairly safe Glucagon-like peptide-1 (GLP-1) agonist. Some peoples genetics predispose them to deregulation of Glucagon-like peptide-1. Oh you are an idiot, and where trying to be funny. https://t.co/4Opaa5dhMJ
The Positive and Negative Effects of GLP-1 Drugs Are Closely Intertwined. Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. #News
Now, the 101 when it comes to the gut’s influence on major hormones is the following: Hormone: Glucagon-like peptide-1 (GLP-1) (regulates appetite plus satiety, and enhances insulin secretion). How the gut influences it: SCFAs stimulate GLP-1 secretion from L-cells in the https://t.co/OhXrvObhMZ
How to keep Ozempic/Wegovy weight loss without the nausea https://www.europesays.com/uk/587452/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…
https://t.co/fPGvOgotcx
How to keep Ozempic/Wegovy weight loss without the nausea https://www.europesays.com/us/392592/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…#us #news #usnews
benefits of weight loss while reducing unwanted side effects. New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied to nausea, thirst, and reward-driven behaviors. GLP-1 drugs include commonly used
How to keep Ozempic/Wegovy weight loss without the nausea https://www.newsbeep.com/ca/294533/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…
How to keep Ozempic/Wegovy weight loss without the nausea https://www.newsbeep.com/us/301959/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…
How to keep Ozempic/Wegovy weight loss without the nausea https://www.newsbeep.com/ie/147622/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…
How to keep Ozempic/Wegovy weight loss without the nausea https://www.newsbeep.com/nz/142349/ New studies are revealing how medications that act on the glucagon-like peptide-1 (GLP-1) system influence brain networks tied…
RT @robertlufkinmd: About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor ago…
Emerging research indicates that hydrogen-rich water (HRW) can increase circulating levels of glucagon-like peptide-1 (GLP-1), an incretin hormone involved in appetite regulation, glucose homeostasis, and insulin secretion. This effect has been observed in human clinical trials https://t.co/HYkFBEaDZZ
RT @robertlufkinmd: About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor ago…
RT @robertlufkinmd: About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor ago…
About 40% of American adults — some 137 million — are eligible to take the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide, said authors of a new study. 10.1001/jamacardio.2024.4657 https://t.co/qLamat5LdD
Martin M. Miner, MD, @BrownMedicine, explores the expanding role of glucagon-like peptide-1 (GLP-1) receptor agonists in men’s health. #Innovations #Urology #MensHealth https://t.co/2IL0lTw06h
Probiotics/GLP-1/Ghrelin/Insulin probiotics can help restore microbial balance and modulate gut hormones, such as glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and ghrelin, which are key regulators of metabolic processes including insulin sensitivity, glucose tolerance, fat
@drabdulhameed07 Metformin is the recommended first-line medication for most patients with type 2 diabetes mellitus. Options for add-on therapy in patients with established cardiovascular disease include glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter 2 inhibitors. GLP-1
Wait till you find out that SCFAs like butyrate can also absolve the need to take GLP-1RA and you can use natural gut health factors here to resolve hunger and drive satiety by promoting peptide YY (PYY) and glucagon-like peptide-1 (GLP-1). https://t.co/Mpmc3rWK1T
https://t.co/BGNbc9oAf2
RT @DrJarhaman: @drabdulhameed07 @IhabFathiSulima @drkeithsiau Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is…
https://t.co/iT7BA5LDwH
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is administered via subcutaneous injection and has been shown to significantly promote weight loss by enhancing insulin secretion in a glucose-dependent manner. https://t.co/IqdEjBdrl1
@drabdulhameed07 @IhabFathiSulima @drkeithsiau Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is administered via subcutaneous injection and has been shown to significantly promote weight loss by enhancing insulin secretion in a glucose-dependent manner.
8/
https://t.co/9iunosPyn6
8/
Les analogues de l’hormone intestinale glucagon-like peptide-1 (GLP-1) ont beaucoup fait parler d’eux ces dernières années, en raison de leur efficacité en matière de perte de poids. Mais ces médicaments ne suffiront pas à vaincre l’obésité, dont la forte progression est due à de nombreux facteurs.
@NatureBiotech Maybe you missed it: Metformin already produces 'endogenous' Ozempic via gut L-cells—a type of enteroendocrine cell of the gastrointestinal tract primarily secreting hormones like glucagon-like peptide-1, GLP-1 downstream. Unsurprisingly, the recently unveiled list of age-related
Wegovy and Ozempic tied to dramatically lower cancer deaths https://www.newsbeep.com/au/279672/ A new study from the University of California San Diego suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, a…
Wegovy and Ozempic tied to dramatically lower cancer deaths https://www.newsbeep.com/nz/131231/ A new study from the University of California San Diego suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, a…
2/ According to @erictopol.bsky.social, this class of drugs - glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 drugs) - has shown a lot of promise for many conditions. And #Tirzepatide is the most potent of the bunch - www.kpbs.org/news/science...
[Futurism]Scientists Say They've Figured Out a Way to Reprogram the Pancreas to Produce GLP-1s Without Ozempic - Futurism Scientists say they've come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1).
“[Ozempic] is based on a hormone called glucagon-like peptide-1 (GLP-1), which is found in the saliva of the Gila monster lizard” But no worries! cause… “This synthetic version is more stable and lasts longer in the body than the natural GLP-1 found in the lizard's saliva.” https://t.co/tqD6ygxWrz
North America Comprehensive Analysis of North America Korea Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2026 | Growth, Strategy & Digital Opp
North America Comprehensive Analysis of North America Korea Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2026 | Growth, Strategy & Digital Opp
https://t.co/LjgjMTXhcA
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}-->https://t.co/FrpjNcGyAm
https://t.co/CkRtYhhYh2
Hey FAT PEOPLE,,, THE MAKER OF OZEMPIC collapses. The active ingredient in Ozempic is semaglutide. This ingredient belongs to a group of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. https://t.co/xER1uVH1XY
$VKTX Highlights new clinical data from the company's VK2735 obesity program were highlighted in a poster presentation at ObesityWeek® 2025, the annual meeting of The Obesity Society (Viking Therapeutics Inc) - VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and
Bariatric (weight-loss) surgery and glucagon-like peptide 1 (GLP-1) medications may offer similar long-term benefits for those with #type2diabetes according to a new study. Learn more about insights from the study here:https://t.co/isdanhiIvG
Biomea Fusion: Investigational small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, BMF-650, showed potent weight loss and good tolerability in obese cynomolgus monkeys $BMEA, #BiomeaFusion, #Biomea https://t.co/IIwSKR1KkA
RT @MargBarAmerica: @TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Admini…
RT @MargBarAmerica: @TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Admini…
RT @MargBarAmerica: @TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Admini…
RT @MargBarAmerica: @TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Admini…
RT @MargBarAmerica: @TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Admini…
@TimJDillon Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to
Bits and Pieces: Patients with DM2 benefit greatly from Glucagon-Like Peptide-1 (GLP-1) agonists and Sodium-Glucose co-Transporter-2 (SGLT2) inhibitors. Unfortunately, they are not used as often as they should be. Many patients with … More 1/2 PhunQuiz https://t.co/crXIVKUKLE
Glucagon-Like Peptide 1 (GLP-1) Action on Hypothalamic Feeding Circuits. Read more in #Endocrinology: bit.ly/3WgA4mq #Glucagon-Like-Peptide-1 #GLP1 #Metabolism #Incretin @endocrinesociety.bsky.social
https://t.co/yBtOm5JmoL
RT @AponiaAnalytics:
@NotOstriching @elonmusk Mounjaro It's designed to stay in the body day & night. Unhealthy in the long run. Glucagon-like peptide-1(GLP-1/Mounjaro) is an inhibitor of adenosine diphosphate(DPP4) creates ATP feeds your mitochondria. Cells starving Hydrocarbons in the day, melatonin at night
@mryoung151 Mounjaro IMO it's designed to stay in the body day & night. Unhealthy in the long run. Glucagon-like peptide-1(GLP-1/Mounjaro) is an inhibitor of adenosine diphosphate(DPP4) creates ATP which feeds your mitochondria. Cells starving Hydrocarbons in the day, melatonin at night.
RT @TheLancetEndo: #Incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)—act as a critical…
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
RT @ABsteward:
North America Comprehensive Analysis of North America Korea Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2026 | Smart Growth, Digital Solution
RT @Helios_Movement: Finally, the 101 when it comes to the gut’s influence on major hormones is the following: Hormone: Glucagon-like pept…
Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs https://t.co/uETB44IFTa #LocalAuthorThursday
Finally, the 101 when it comes to the gut’s influence on major hormones is the following: Hormone: Glucagon-like peptide-1 (GLP-1) (regulates appetite plus satiety, and enhances insulin secretion). How the gut influences it: SCFAs stimulate GLP-1 secretion from L-cells in the https://t.co/S5kS0337zs
VLCC, once synonymous with weight loss in India, now have to contend with glucagon-like peptide-1 (GLP-1) drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. Despite this, PE firm Carlyle Group bought a 66% stake in VLCC for around Rs 2,600 crore ($300 million) in 2023. https://t.co/Ck7p5z6kPW
VLCC, once synonymous with weight loss in India, have to contend with the age of glucagon-like peptide-1 (GLP-1) drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound. Despite this, private equity firm Carlyle Group bought a 66% stake in VLCC for around Rs 2,600 crore ($300 million) in 2023.
STEP-HFpEF trial demonstrated that Glucagon-like peptide-1 (GLP-1) receptor agonists significantly improve symptoms, physical function, and weight in patients with obesity-related HFpEF. Safe to say these medicines (and losing weight, really) are going to be effective for most https://t.co/ShoQ50Y29l
STEP-HFpEF trial demonstrated that Glucagon-like peptide-1 (GLP-1) receptor agonists significantly improve symptoms, physical function, and weight in patients with obesity-related HFpEF
https://t.co/70YZp0r75B
RT @Cipla_Global: Cipla has the rights to distribute and promote Yurpeak®, a prescription based the first and only dual agonist of glucose-…
@jrkelly “GLP-3” is even better! Retatrutide It is a "triple-agonist" that imitates three gut hormones to help regulate appetite and blood sugar: glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP)
RT @vraeae91: Ozempic® (brand name) is a semaglutide which falls under the class of Glucagon-Like Peptide-1 (GLP-1) Agonist which are drugs…
Ces derniers ont découvert que les médicaments à base de glucagon-like peptide 1 (GLP-1) peuvent interférer avec les résultats des imageries médicales, occasionnant des examens inutiles, rapporte le média britannique The Independant. https://t.co/JADvO6jsZT
Product Description Exendin(9-39) amide acetate is a synthetic peptide derived from the native exendin-4 sequence, designed as a selective glucagon-like peptide-1 (GLP-1) receptor antagonist. #GMP arizona-mall.com/product/exen...
Product Description Ribupatide is an advanced dual incretin receptor agonist designed to activate both glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. #GMP arizona-mall.com/product/ribu...
Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY) https://www.newsbeep.com/nz/87093/ Specialty Please choose I’m not a medical professional. Allergy and Immunology …
#Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical link connecting digestion, metabolism, & cardiovascular function, supporting physiological adaptations to nutrient intake thelancet.com/journals/lan... #GLP-1 #GIP #MedSky #EndoSky
Product Description Enicepatide is a potent dual receptor agonist targeting both gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, two key regulators of insulin secretion and glucose metabolism. #GMP arizona-mall.com/product/enic...
Product Description Enicepatide is a potent dual receptor agonist targeting both gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, two key regulators of insulin secretion and glucose metabolism. #GMP arizona-mall.com/product/enic...
Product Description Berobenatide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), designed to selectively activate GLP-1 receptors with enhanced metabolic stability and receptor affinity. #GMP arizona-mall.com/product/bero...
Glucagon-like peptide-1 (GLP-1) drugs appear to slow the speed at which alcohol enters the bloodstream, which also diminishes its effects on a person’s brain, according to new pilot study results. www.healthday.com/health-news/...
Product Description Zovaglutide (CAS No. 3013543-64-8) is a synthetic peptide that functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 receptors are a critical component in glucose homeostasis, insulin secretion, and appetite regulation. #CGMP arizona-mall.com/product/zova...
Within minutes of starting to eat, cells in your gut rev into action and start secreting two peptide hormones--glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones are known as incretins. More at PDB-101:
Product Description Imapextide (CAS No. 3004569-93-8) is a synthetic glucagon-like peptide-1 (GLP-1) receptor antagonist designed to block the actions of endogenous GLP-1 (glucagon-like peptide-1). #CGMP arizona-mall.com/product/imap...
@Rainmaker1973 Just to be clear, medical science has known the body naturally produces Glucagon-Like Peptide-1 (GLP-1). It is known to be produced in the intestines, primarily from L-cells, in response to a meal.
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
Product Description Utreglutide (CAS 2460862-12-6) is a potent glucagon-like peptide-1 (GLP-1) receptor agonist, specifically designed to mimic the activity of endogenous incretin hormones. #GMP arizona-mall.com/product/utre...
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
RT @NEJM: Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the trea…
Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes. Research findings from the ACHIEVE-1 phase 3 trial are summarized in a new Quick Take video. nej.md/42tGbHh
Orforglipron is an oral, small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes. Research findings from the ACHIEVE-1 phase 3 trial are summarized in a new Quick Take video. https://t.co/NBFIqmeGy5 https://t.co/O6rXMQMso2
How do #weightloss medications affect our relationship with food? https://t.co/QvRY69Vp2H Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (#Mounjaro) have been shown to help people living with obesity lose weight. By mimicking the
Curious how GLP-1 and GLP-1/GIP medications work? ✨ These medications work by mimicking two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). https://t.co/1itMH8TI6T
How do weight loss medications affect our relationship with food? | Obesity https://www.newsbeep.com/uk/148767/ 1. Reduced hunger Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Mounjaro) have been shown…
How do weight loss medications affect our relationship with food? | Obesity https://www.newsbeep.com/ie/32222/ 1. Reduced hunger Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Mounjaro) have been shown…
This study investigated the effects of orally administered l-lysine (Lys) on glucagon-like peptide-1 (GLP-1) secretion in rats.
Incretins & cardiovascular system: bridging digestion with metabolism - Lancet Diabetes & Endocrinology. incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)—act as critical link connecting digestion, https://t.co/BkRxZ8wWfw
RT @TSTHZeee: WATCHLIST SEP 19 2025 $NVO EMA's CHMP Adopted Positive Opinion For Kyinsu For The Treatment Of Adults With Type 2 Diabetes I…
WATCHLIST SEP 19 2025 $NVO EMA's CHMP Adopted Positive Opinion For Kyinsu For The Treatment Of Adults With Type 2 Diabetes Insufficiently Controlled On Basal Insulin Or Glucagon-like Peptide 1 (GLP-1) Receptor Agonists $BNAI BEN Appoints Dr. Ruy Carrasco to Board; Company to
https://t.co/52V8bXiYVc
Dr Dinah Parums | Parums DV. Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity. Med Sci Monit. 2024;30:e946675. doi: 10.12659/MSM.946675. PMID: 39350608. https://t.co/C19BGcv80w
“plans to launch clinical trials for several interventions. Those include glucagon-like peptide-1 (GLP-1) drugs, like tirzepatide; stellate ganglion block..and low-dose naltrexone” cen.acs.org/pharmaceutic...
“plans to launch clinical trials for several interventions. Those include glucagon-like peptide-1 (GLP-1) drugs, like tirzepatide; stellate ganglion block..and low-dose naltrexone” https://t.co/bABF7ze6L3
New Molecules and Indications for GLP-1 Medicines. Glucagon-like peptide-1 (GLP-1) medicines, defined herein as any medicine that exerts its actions in part thro GLP-1 receptor, initially approved for (T2D), https://t.co/TZf8lOgKnV
RT @JWatch: Glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to excess risk for some cancers. However, weight loss with t…
RT @JWatch: Glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to excess risk for some cancers. However, weight loss with t…
RT @JWatch: Glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to excess risk for some cancers. However, weight loss with t…
Glucagon-like peptide-1 (GLP-1) receptor agonists have been linked to excess risk for some cancers. However, weight loss with these drugs also could lower risk for obesity-related cancers. Three large observational studies provide more data. https://t.co/tnP9TNad7z #GLP1 #cancer https://t.co/WZN9HqKLfO
GLP-1 medications are a class of drugs that mimic the natural Glucagon-Like Peptide-1 (GLP-1) hormone to treat type 2 diabetes and obesity. They work by increasing insulin release, slowing stomach emptying, and promoting feelings of fullness (satiety). These medications can https://t.co/douAyJhDTs
The GLP-1 refers to glucagon-like peptide-1 (GLP-1) medications, which are mainly used for diabetes and obesity treatment,but are also beginning to reshape adjacent sectors like digital health,food and beverage and medtech. The global GLP-1 market is experiencing explosive growth
“RECOVER plans to launch clinical trials for glucagon-like peptide-1 (GLP-1) drugs, like tirzepatide; stellate ganglion block; low-dose naltrexone” “RECOVER will also allocate additional funding for an ongoing trial of baricitinib, a Janus kinase (JAK) inhibitor” cen.acs.org/pharmaceutic...
@theliverdr Is there any benefit in switching from another glucagon-like peptide-1 (GLP-1) type drug to Mounjaro?
Dr Dinah Parums | Parums DV. Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity. Med Sci Monit. 2024;30:e946675. doi: 10.12659/MSM.946675. PMID: 39350608. https://t.co/oSfnLgi1Ci
@hubermanlab Super insightful take on personalizing metabolic health...love how it spotlights unique needs for fiber, carbs, and diabetes subtypes from Dr. Snyder's chat! We've delved into research on glucagon-like peptide-1 (GLP-1), which amps up insulin secretion, curbs glucagon, and
@isaac_saas Glucagon-like peptide-1 (GLP-1) receptor agonists that can help reduce LDL cholesterol and triglycerides, potentially supporting metabolic health during hormone optimization. It could complement routines like yours for balanced wellness without overhauling things
@sanilrege @psycheureka We've come across research on glucagon-like peptide-1 (GLP-1) that helps regulate brain insulin sensitivity, potentially easing depression through neurotransmitter control and reduced neuroinflammation. ...It might work alongside options like metformin for balanced, low-key
Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2026 | Market Share & Regional Forecasts 2033
#QUIZ: Haben Glucagon-like peptide 1(GLP-1)-Rezeptoragonisten bei Patienten mit Diabetes entzündungshemmende Wirkungen? #MedTwitter https://t.co/MjhY5a3bzT https://t.co/rqgJ5A134q
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}-->https://t.co/71OYVkBsvo
https://t.co/3df50OnclR
<!--td {border: 1px solid #cccccc;}br {mso-data-placement:same-cell;}-->https://t.co/8O3F5uDMtg
New GLP1-GIP needs only once monthly dosing... What will that mean for full stomachs??? "Maridebart cafraglutide combines glucagon-like peptide-1 (GLP-1) receptor agonism and glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. It has t1/2 ~ 21 d https://t.co/E2kWExJsZX
https://t.co/ZzVtDtbwNk
#WHO has now added a new set of #drugs for obesity & diabetes to its essential medicines list, alongside treatments for cancer & cystic fibrosis. Says,cheap generic versions of glucagon-like peptide-1 (GLP-1) drugs should also be made available for people in developing countries!
@MarioNawfal What is Orforglipron? “Orforglipron (LY3502970) is an investigational, once-daily oral medication developed by Eli Lilly and Company, initially discovered by Chugai Pharmaceutical Co. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists and is being
Glucagon-like peptide-1 (GLP-1) medicines & heart protection: hype or evidence? SELECT: semaglutide 2.4 mg cut heart attack, stroke, or cardiovascular death by ~20% in adults with overweight or obesity and heart disease, without diabetes. (New England Journal of Medicine, 2023). https://t.co/j5ARafuxvk
Finally, the 101 when it comes to the gut’s influence on major hormones is the following: Hormone: Glucagon-like peptide-1 (GLP-1) (regulates appetite plus satiety, and enhances insulin secretion). How the gut influences it: SCFAs stimulate GLP-1 secretion from L-cells in the https://t.co/xks6daVNh0
The first participant has been dosed in the Phase 1 trial of our Precision Endocrine Peptide (PEP) glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug to treat #obesity. https://t.co/PGSNe9pVZA https://t.co/Il9GfGxL5G
@nphatesyou @PopCrave Harvard researchers have developed life-changing therapies for a range of diseases, including new treatments for cancer, diabetes, and sickle cell disease. They also discovered glucagon-like peptide-1 (GLP-1), a molecule that revolutionized obesity treatments.
Acylated ghrelin, active glucagon-like peptide-1 (GLP-1), plasma glucose, insulin, blood lactate, and appetite perceptions were measured pre-exercise, 0 min, 30 min, 60 min, and 120 min post-exercise.
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
@FoodnNutriti0n Cayenne pepper, due to its main active component capsaicin, shows promise in combating insulin resistance by potentially enhancing insulin sensitivity, promoting fat oxidation, and increasing the production of glucagon-like peptide-1 (GLP-1). Studies in animals have https://t.co/T6rlrTZeMq
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
Older Adults Omitted from Key Obesity Drug Trials In the realm of medical science, particularly in the quest to alleviate the global epidemic of obesity, blockbuster treatments have emerged in recent years, notably the glucagon-like peptide-1 (GLP-1) receptor agonists and the new generation of…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
Glucagon-like peptide-1 (GLP-1) an amino-acid-long peptide hormone, produced & secreted by intestinal enteroendocrine L-cells & neuron tracts in brainstem upon food consumption GLP-1 & Diabetes = Dietary Excess a Metabolic Poison https://t.co/gdDGwMGf5r
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
@madcat007 @vbislands @KeithOlbermann Care to plot Trump's decline versus Biden's on an age-based basis? Btw, glucagon-like peptide-1 (GLP-1) receptor agonists only mitigate body fat as opposed to cranial plaque.
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
Incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)—act as a critical link connecting digestion, metabolism, and cardiovascular function, supporting physiological adaptations to nutrient intake. https://t.co/dVUUXTXqmg
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
a gentler take on the GLP-1 craze? https://www.newsbeep.com/au/108461/ On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
a gentler take on the GLP-1 craze? https://www.newsbeep.com/us/122299/ On TV, in magazines and on social media: glucagon-like peptide 1 (GLP-1) agonist drugs such as…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
RT @TheLancetEndo: Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical lin…
Incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical link connecting digestion, metabolism, & cardiovascular function, supporting physiological adaptations to nutrient intake www.thelancet.com/journals/lan... #MedSky #EndoSky #GastroSky
Can a Keto Diet be the GLP-1 of Psychiatry? (MedPage Today) -- Glucagon-like peptide-1 (GLP-1) agonist medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) have taken the world by storm over the past few years. People are losing tremendous amounts of weight...…
GLP-1 Drugs Like Ozempic Promote Weight Loss, But What Happens After You Stop Taking Them? Glucagon-like peptide-1 (GLP-1) agonists are powerful weight loss medications that can help you lose 10 to 20 percent of your body weight. They can also help regulate blood sugars in those with diabetes as…
GLP-1 Drugs Like Ozempic Promote Weight Loss, But What Happens After You Stop Taking Them? Glucagon-like peptide-1 (GLP-1) agonists are powerful weight loss medications that can help you lose 10 to 20 percent of your body weight. They can also help regulate blood sugars in those with diabetes as…
Zenagamtide | GMP Supplier for Research Use Zenagamtide is a potent glucagon-like peptide-1 (GLP-1) and amylin receptor agonist designed for advanced biomedical and metabolic research. Manufactured under GMP standards, available for both bulk and retail supply. For laboratory research use…
Timeline: How Quickly Does Semaglutide Suppress Appetite? Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, typically begins to suppress appetite within the first week. It mimics GLP-1 hormone effects, enhancing insulin secretion and promoting fullness. Most users notice decreased…
Answer: a Tirzepatide is the only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) currently approved by the FDA.
GLP-1s’ Preoperative Use Requires Safety Considerations https://www.newsbeep.com/au/71724/ Preoperative glucagon-like peptide-1 (GLP-1) receptor agonist therapy did not increase perioperative risks in individuals with obesity or overweight,…
Ocular Side Effects Associated with Semaglutide: New Insights Recent investigations into the safety profile of semaglutide, a widely prescribed glucagon-like peptide-1 (GLP-1) receptor agonist, have yielded compelling insights into its ophthalmic effects. Semaglutide, primarily utilized to enhance…
This systematic review examined the effects of Bifidobacterium, isolated from skin microbiota, on glucagon-like peptide-1 (GLP-1) production. The researchers conducted a comprehensive literature search and identified 267 relevant studies.
Strategies for Maintaining Muscle Mass While Using GLP-1 Weight Loss Medications Sun 1st Dec, 2024 Strategies for Maintaining Muscle Mass While Using GLP-1 Weight Loss Medications The introduction of glucagon-like peptide-1 (GLP-1) medications, including Wegovy and Zepbound, has revolutionized…
Strategies for Maintaining Muscle Mass While Using GLP-1 Weight Loss Medications Sun 1st Dec, 2024 Strategies for Maintaining Muscle Mass While Using GLP-1 Weight Loss Medications The introduction of glucagon-like peptide-1 (GLP-1) medications, including Wegovy and Zepbound, has revolutionized…
Significant Portion of Eligible Adults for Weight Loss Medications Do Not Meet Clinical Trial Criteria Tue 3rd Dec, 2024 Recent research indicates that approximately one-third of U.S. adults who qualify for weight loss treatments involving glucagon-like peptide-1 (GLP-1) receptor agonists and…
Significant Portion of Eligible Adults for Weight Loss Medications Do Not Meet Clinical Trial Criteria Tue 3rd Dec, 2024 Recent research indicates that approximately one-third of U.S. adults who qualify for weight loss treatments involving glucagon-like peptide-1 (GLP-1) receptor agonists and…
"We propose that incretin hormones—glucagon-like peptide-1 (GLP-1) & glucose-dependent insulinotropic peptide (GIP)—act as a critical link connecting digestion, metabolism, & cardiovascular function, supporting physiological adaptations to nutrient intake" www.thelancet.com/journals/lan... #EndoSky
Giving this one a screenshot because it's paywalled; link.springer.com/article/10.1.... Basically implying that bacterial infection can lead to dysregulation of GLP-1.
In patients with #type2diabetes and monoclonal gammopathy of undetermined significance, GLP-1 RA use was associated with reductions in major adverse cardiovascular and cerebrovascular events and all-cause mortality. https://ja.ma/3ZWTf72
GLP-1 Drugs Show Promise for Childhood Obesity In a promising advancement within pediatric obesity treatment, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a groundbreaking therapeutic option recently approved by both the U.S. Food and Drug Administration (FDA) and the European…
Ecnoglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist analogue, similar to the blockbuster obesity drug semaglutide. These drugs mimic the hormone GLP-1, which is involved in regulating appetite and managing blood-sugar levels. 2/3
Mounjaro is a single molecule that acts as both a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. This means it helps regulate blood sugar levels by stimulating hormones that control insulin release and suppress appetite.
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users www.medpagetoday.com/meetingcover...
GLP-1’s Role in Synaptic Control of Energy Balance In the complex biological orchestra that governs energy balance in mammals, the hormone glucagon-like peptide-1 (GLP-1) holds a critical position, particularly within the central nervous system. Beyond its well-established peripheral roles in…
Why GLP-1s like Ozempic should be available over the counter When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes. But this new drug class had the potential…
When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes. But this new drug class had the potential to treat a h... | Details | Interest | Feed |
Ozempic Breath: Causes, Symptoms & Treatment Understanding Ozempic and its Side Effects Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and manage weight. However, like many medications Ozempic has side effects. Common side effects include nausea…
The third reason is because there has been a huge wave of new prescription weight loss drugs called glucagon-like peptide-1 (GLP-1) receptor agonist drugs over the past 5 years. (7/10)
This Daily Pill May Work as Well as Ozempic, Wegovy Injections A daily pill from Eli Lilly could be as effective for weight loss and blood sugar control as injections like Ozempic or Wegovy, according to April data from a Phase 3 clinical trial. The glucagon-like peptide-1 (GLP-1) oral medication,…
Study reveals additional health perk of weight-loss medications Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and obesity, have been shown to have the surprising secondary benefit of reducing alcohol intake. A…
Why You Might Tolerate One Weight Loss Drug Better Than Another https://www.europesays.com/uk/105144/ Prescriptions for Ozempic, Mounjaro, and other glucagon-like peptide-1 (GLP-1) receptor agonist drugs have skyrocketed in recent years. But…#uk #news #uknews
"Elimination of coverage for Glucagon-Like Peptide-1 (GLP-1) drugs for weight loss effective January 1, 2026"
Why You Might Tolerate One Weight Loss Drug Better Than Another Prescriptions for Ozempic, Mounjaro, and other glucagon-like peptide-1 (GLP-1) receptor agonist drugs have skyrocketed in recent years. But even though the medications are used for similar purposes, people often have vastly different…
"Glucagon-like peptide-1 (GLP-1) medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were in shortage starting in 2022. During that time, compounded versions of these medications became a more accessible option. Compounded GLP-1s are not FDA approved." - GoodRx
The data on flozins and GLP1RAs is mixed The toxic potential is pretty real - but with such mixed studies - we really need higher quality data #NephSky #PregnancyMed
Ozempic (Semaglutide) Understanding Ozempic: Benefits for Type 2 Diabetes and Weight Loss What is Ozempic and How Does It Work? Ozempic is a prescription medication primarily used for the management of type 2 diabetes. Its active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1)…
Ozempic (Semaglutide) Understanding Ozempic: Benefits for Type 2 Diabetes and Weight Loss What is Ozempic and How Does It Work? Ozempic is a prescription medication primarily used for the management of type 2 diabetes. Its active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1)…
How and Where To Get Zepbound Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Taking Zepbound may help with weight loss when…
Das Pharmaunternehmen Eli Lilly & Co. steht kurz davor, mit dem oralen Glucagon-Like Peptide-1 (GLP-1)-Rezeptoragonisten Orforglipron ein neues Kapitel in der Behandlung von #Adipositas und #Diabetes einzuleiten.
Not all GLP-1 medications are the same. Wegovy, Ozempic, and Mounjaro serve different purposes in managing diabetes and obesity. Swipe to learn more, or schedule an appointment for expert guidance.
#Medsky
What are your experiences with glucagon-like peptide-1 (GLP-1) drugs like Ozempic, Wegovy, Mounjaro, and Trulicity?? Answer surveys for a chance to win a $150 gift card
Congratulations to #SinaiHealth’s Dr. Daniel Drucker #LTRI on receiving the 2025 Breakthrough Prize in Life Sciences for his groundbreaking work on glucagon-like peptide 1 (GLP-1)!
Chronic conditions and costly drugs, such as GLP-1s, are expected to raise health care spending. Learn more about the impact of chronic diseases in the latest #NIHCM Infographic: bit.ly/4jffH2l
Ozempic (Semaglutide) Understanding Ozempic: Benefits for Type 2 Diabetes and Weight Loss What is Ozempic and How Does It Work? Ozempic is a prescription medication primarily used for the management of type 2 diabetes. Its active ingredient, semaglutide, is a glucagon-like peptide-1 (GLP-1)…
What are your experiences with glucagon-like peptide-1 (GLP-1) drugs like Ozempic, Wegovy, Mounjaro, and Trulicity?? Answer surveys for a chance to win a $150 gift card
D Express uk Glucagon-like peptide 1 (GLP-1) drugs like Ozempic, Wegoyvy, Mounjaro, and Zepbound, used to treat type 2 diabetes and obesity, in rare cases, have been found to cause severe eyesight loss, according to a small study at the University of British Columbia published in JAMA Ophthalmology
Glucagon-like peptide 1 (GLP-1) drugs like Ozempic, Wegoyvy, Mounjaro, and Zepbound, used to treat type 2 diabetes and obesity, in rare cases, have been found to cause severe eyesight loss, according to a small study at the University of British Columbia published in JAMA Ophthalmology.
What are your experiences with glucagon-like peptide-1 (GLP-1) drugs like Ozempic, Wegovy, Mounjaro, and Trulicity?
"You’ve Already Paid $6Billion For Weight-Loss Drugs You Can’t Afford" www.levernews.com/youve-alread... ~ According to data shared by researchers at Bentley University, the NIH spent $6.2B 1980-2024 for research on glucagon-like peptide-1 (GLP-1) and use of GLP-1 drugs to treat diabetes, obesity, ~
Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut upon food consumption. Ozempic et al work by faking the presence of GLP-1 in the brain, making your system think you've eaten already.
After 2 years of shortages, the compounding market for glucagon-like peptide 1 (GLP-1) medication has exploded to include telehealth companies and compounding pharmacies. This Medical News article discusses GLP-1 drugs. #MedSky
Is this GLP-1.2? New generation of weight-loss drugs moving in Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are forcing the industry to think about…
“In 1986, through years of work on stomach ulcers, a Danish scientist, along with others at Harvard Medical School and the University of Toronto, discovered the hormone glucagon-like peptide-1, GLP-1, which governs a person’s appetite.
Ophthopedia Update: This Issue at a Glance: Using electronic medical records data from TriNetX, a large multinational dataset, Muayad et al (p. 271) conducted a retrospective cohort study to compare the effects of glucagon-like peptide 1 (GLP-1) receptor… #Ophthalmology #ophthotwitter #eyecare
Weight-loss, diabetes drugs linked to vision problems in small study Popular drugs for diabetes and weight loss could have an unexpected side effect. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small…
FSRH Statement: Glucagon-like peptide-1 (GLP-1) agonists and oral contraception #wegovy #mounjaro #ozempic www.fsrh.org/Public/Publi...
We have published a statement about glucagon-like peptide-1 (GLP-1) agonists and oral contraception. We have also produced an information leaflet for clinicians to share with patients, which can be found in the statement.
At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic optic neuropathy. jamanetwork.com/journals/jam...
Ein breites Wirkungsspektrum der "Abnehmspritzen"... https://t.co/Nmwefer5cj
How do weight loss drugs like Wegovy work? In the latest edition of #PeriodicGraphics in @cenmag.bsky.social we take a look at the science and history behind these drugs: cen.acs.org/biological-c... #ChemSky
This edition of #PeriodicGraphics describes the science behind glucagon-like peptide 1 (GLP-1) receptor agonists, the history of the drugs, and the conditions they can and might one day treat: cen.acs.org/biological-c...
After 2 years of shortages, the compounding market for glucagon-like peptide 1 (GLP-1) medication has exploded to include telehealth companies and compounding pharmacies. This Medical News article discusses GLP-1 drugs. #MedSky
Tirzepatide Factory wholesale Tirzepatide is a drug developed by Eli Lilly and Company to treat type 2 diabetes and obesity! 7], the drug is a combination of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP- 1) Dual agonist of the receptor [9]. Its commercial brands…
Obesity is a hugely complex issue. An excellent editorial this month in the @bmj.com from @drjuanfranco.bsky.social and @iddocjen.bsky.social on how the new drugs now available aren’t necessarily a magic bullet. Even if they are, lifelong support is needed for those affected. #MedSky #Obesity
"Wegovy" sounds like some kind of Biblical heresy
Have you seen their new money grab? glp1 and addiction Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes and weight loss, show promise in treating addiction disorders.
Insurers said one major driver of higher premiums is the growing popularity of a relatively new class of injectable drugs to manage diabetes and weight loss. These glucagon-like peptide-1 (GLP-1) drugs include Wegovy, Ozempic and Mounjaro, and have list prices of roughly $1,200 per person per mth
Ophthopedia Update: GLP-1 RECEPTOR AGONISTS USE AND INCIDENCE OF GLAUCOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS: In diabetics, glucagon-like peptide 1 (GLP-1) receptor agonists (RA) may protect against microvascular alterations and oxidative stress, both of… #Ophthalmology #Ophthotwitter #Scicomm
active ingredient but can be used to treat different conditions. Zepbound works by activating receptors of hormones secreted from the intestine (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) to reduce appetite and food intake. By reducing body weight,
2024 Lasker-DeBakey Clinical Medical Research Award winner Svetlana Mojsov describes her discovery of glucagon-like peptide (GLP)-1, the biologically active incretin that led to development of effective GLP-1 analogues for diabetes and obesity. https://ja.ma/4eQXCoD
Why eating protein makes you feel more full (satiated)
Glucagon-like peptide-1 (GLP-1) receptor agonists used to help people lose weight may reduce the risk of worsening kidney function, kidney failure and dying from kidney disease by a fifth.
What helps fight against diabetes, obesity, heart disease, arthritis and kidney disease? GLP-1 agonists. True wonder drugs. Popular diabetes and obesity drugs also protect kidneys, study shows The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on…
The blockbuster drug Glucagon-like peptide 1 (GLP-1)
Lirafit Pen Injection Lirafit Pen Injection contains liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. www.milanmedicals.com/lirafit-pen-...
GLP-1 as a pan addiction agent? “Research is increasingly pointing towards the glucagon-like peptide-1 (GLP-1) system as a significant player in the neurobiology of addictive behaviours,…… Article
"Ozempic (Semaglutide) belongs to the class of drugs called Glucagon-like peptide-1 (GLP-1) receptor agonists. They mimic the actions of the hormone GLP-1 made by the small intestine, which the gut releases after eating."
Mice studies suggest that gut microbiome friendly oat and barley fiber containing beta-glucan can increase butyrate in the gut. "Butyrate induces the release of glucagon-like peptide-1 (GLP-1), which is the natural protein that synthetic drugs like Ozempic mimic to stimulate insulin release." […]
Gov't Cracking down on Overseas Direct Purchase of GLP-1 Drugs https://www.byteseu.com/504211/ Photo : YONHAP News The Ministry of Food and Drug Safety and the Korea Customs Service are cracking down on overseas direct purchases of glucagon-like peptide 1 (GLP-1) drugs, including the injectable …
Animal studies and analyses of electronic health records suggest that the latest wave of weight-loss drugs — known as glucagon-like peptide 1 (GLP-1) receptor agonists — cut many kinds of craving or addiction, from alcohol to tobacco use. www.nature.com/articles/d41...
@euronews: Weight loss market: Smaller rivals muscle in on Eli Lilly and Novo Nordisk. Analysts project that the market for glucagon-like peptide 1 (GLP-1) drugs could reach a range between $150bn (€135bn) and $200bn (€180bn) by 2030s. https://t.co/Etaq8sqW15
A new side effect of GLP-1 receptor agonists like Ozempic and Wegovy? FDA now says it is "evaluating the need for regulatory action" over a potential signal of "Dysaesthesia" (aka skin pain) www.fda.gov/drugs/questi...
[ad_1] Wegovy was simply authorised in China. Novo Nordisk (NVO -1.21%) has emerged as one of many largest names within the pharmaceutical world because of its sturdy line of glucagon-like peptide-1 (GLP-1) medicines. The Danish drugmaker develops Ozempic,... https://igkstore.com/?p=25854
Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change https://www.medrxiv.org/content/10.1101/2024.05.06.24306943v1
"Even as obesity treatments Ozempic and Mounjaro continue their surge in popularity, drug hunters are asking whether it is possible for people to lose weight on these glucagon-like peptide-1 (GLP-1) agonists without losing muscle." www.nature.com/articles/s41...
Now out this week in their quarterly report FDA confirms it is "evaluating the need for regulatory action" after reports in patients taking GLP-1 medications like Ozempic and Wegovy of alopecia, aspiration, suicidal ideation www.fda.gov/drugs/questi...
RT @dokter_kampung: @LtdAkbar Konsep hiperglukagonemi sebetulnya juga pernah dikemukakan oleh Unger di tahun 70an. Tapi dengan kompromi hip…
@LtdAkbar Konsep hiperglukagonemi sebetulnya juga pernah dikemukakan oleh Unger di tahun 70an. Tapi dengan kompromi hipoinsulinemi sehingga dikenal sebagai konsep kausalitas bihormonal. Namun temuan menunjukkan dominasi hiperglukagonemi https://t.co/5lCMwXrO1U
#医療情報 #日本 ＃不良美容外科 ＃医師法改正 #ダイエット 日本の非専門医（美容外科・内科）のいくつかの医療行為・処方に関しては素人なので規制するべき https://t.co/sONDkdWI5L
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
RT @marubioendocr: Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descar…
Si quieres una SUPER-REVIEW de GLP1 (casi 1000 citas) de autores como Bloom, Drucker, Holst, Meir, Nauck, Tschöp, descarga: https://t.co/YG5gDNiha3 @mdballesteros @isidoro_cano @diabeteSEEN @fjavesc @DiegoBellido2 @mbotana @sandradurandoc @ObesitySeen @Judithendo https://t.co/CFJEu6Vqcg
M
DD
PY
VB
VB
B
JZ
WO
SL
AA
DM
PL
KD
HR
CS
SM
J
JP
JP
JC
JS
JD
JS
JN
JM
JO
JO
JF
JO
DJ
Iº
SN
E
PZ
PL
LR
JK
GF
SS
UB
KB
MG
T
AA
RM
GU
PM
MM
U
DD
DH
MT
NS
IN
PK
TJ
RW
MN
VP
SM
LM
TC
D
HN
P
AB
D
W
JV
H
P
SR
R
AA
GO
PS
EC
DP
KA
H
LH
AG
M
ML
TK
RK
VR
SL
CG
PR
KD